Article thumbnail
Location of Repository

Effectiveness of MF59TM Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the

By Leonoor Wijnans, Jeanne Dieleman, Bettie Voordouw and Miriam Sturkenboom


Background: The aim of the present study was to estimate the effectiveness of the MF59TM-adjuvanted influenza A(H1N1)pdm09 vaccine against medically attended influenza-like illness and RT-PCR confirmed influenza in the at-risk population and persons over 60 in the Netherlands. Methods: We conducted a retrospective cohort study in a Dutch based GP medical record database between 30 November 2009 and 1 March 2010 to estimate the vaccine effectiveness against influenza-like illness. Within the cohort we nested a test negative case-control study to estimate the effectiveness against laboratory confirmed influenza. Results: The crude effectiveness in preventing diagnosed or possible influenza-like illness was 17.3 % (95%CI:28.5%–36.9%). Of the measured covariates, age, the severity of disease and health seeking behaviour through devised proxies confounded the association between vaccination and influenza-like illness. The adjusted vaccine effectiveness was 20.8 % (95%CI:25.4%, 40.5%) and varied significantly by age, being highest in adults up to 50 years (59%, 95%CI: 23%, 78%), and non-detectable in adults over 50 years. The number of cases in the nested case control study was too limited to validly estimate the VE against confirmed influenza. Conclusions: With our study we demonstrated that the approach of combining a cohort study in a primary health car

Year: 2013
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.